4//SEC Filing
Camaisa Allan 4
Accession 0001493152-24-050675
CIK 0001855485other
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 9:29 PM ET
Size
6.1 KB
Accession
0001493152-24-050675
Insider Transaction Report
Form 4
Camaisa Allan
DirectorCEO, President and Chairman10% Owner
Transactions
- Sale
Common Stock
2024-12-17$1.62/sh−10,000$16,200→ 66,712 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected for tax planning purposes. The reporting person undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request of the SEC staff, the Issuer or a security holder of the Issuer.
- [F2]Includes 6,557 shares of Common Stock directly held by Allan Camaisa. Does not include (i) 14,000 shares of Common Stock issuable upon exercise of options held by Mr. Camaisa under the 2023 Equity Plan, (ii) 6,445 shares of Common Stock issuable upon exercise of options held by Mr. Camaisa under the 2019 Equity Plan, (iii) 46,972 shares of Common Stock issuable upon exercise of warrants within sixty (60) days held by Mr. Camaisa, (iv) 70,760 shares of Common Stock issuable upon exercise of options held by AJC Capital, LLC ("AJC"), (v) 203,954 shares of Common Stock issuable upon exercise of options held by AJC, (vi) 281,513 shares of Common Stock held by AJC, and (vii) 608,383 shares of Common Stock held by Jamir Trust. Mr. Camaisa is the sole managing member and owner of AJC and the sole trustee of Jamir Trust; as such, Mr. Camaisa may be deemed to have beneficial ownership of the Common Stock held by AJC and Jamir Trust.
Documents
Issuer
Calidi Biotherapeutics, Inc.
CIK 0001855485
Entity typeother
Related Parties
1- filerCIK 0001990674
Filing Metadata
- Form type
- 4
- Filed
- Dec 17, 7:00 PM ET
- Accepted
- Dec 18, 9:29 PM ET
- Size
- 6.1 KB